Bernard Coulie - 20 Jan 2026 Form 4 Insider Report for PLIANT THERAPEUTICS, INC. (PLRX)

Reporting relationship: President and CEO, Director
Issuer ticker: PLRX
Reported as of: 20 Jan 2026
Net transaction value: -$114,400
SEC form: 4
Accepted by SEC: 22 Jan 2026, 21:38:33 UTC
Prior SEC filing: 20 Jun 2025
Next SEC filing: 26 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Jennifer Woo, attorney-in-fact

Key filing fact

Bernard Coulie filed Form 4 for PLIANT THERAPEUTICS, INC. (PLRX) on 22 Jan 2026.

Key facts

This page summarizes Bernard Coulie's Form 4 filing for PLIANT THERAPEUTICS, INC. (PLRX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 22 Jan 2026, 21:38.

Change

Previous filing in this sequence was filed on 20 Jun 2025.
Current net transaction value: -$114,400.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001808895 Primary reporting owner

Coulie Bernard

Relationship: President and CEO, Director
Address: C/O PLIANT THERAPEUTICS, INC., 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO
Signature: /s/ Jennifer Woo, attorney-in-fact
Signature date: 22 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PLRX transaction

Common Stock

Sale

Transaction value: $114,400
Shares: -89,375
Change %: -15%
Price: $1.28
Shares after: 505,601
Date: 20 Jan 2026
Ownership: Direct
Footnotes: F1, F2

PLRX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 409,317
Date: 20 Jan 2026
Ownership: See footnote
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

Represents a nondiscretionary sale by the plan on behalf of the Reporting Person in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's share represents the weighted average of all shares sold by a broker at prices ranging from $1.245 to $1.33, inclusive, on January 20, 2026 through January 22, 2026 on behalf of a group on employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted restricted stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4.

Footnote F2

Includes 1,959 shares of Common Stock acquired by the Reporting Person pursuant to an Employee Stock Purchase program.

Footnote F3

Shares held by The Coulie/Leyman Family Trust. The Reporting Person and his spouse serve as trustees for the trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.